Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?

類似資料

• Should we try the antiinflammatory natural product, celastrol, for COVID‐19?
  著者:: Habtemariam, Solomon, 等
  出版事項: (2020)
• Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?
  著者:: Nabavi, Seyed Fazel, 等
  出版事項: (2020)
• May we target double‐membrane vesicles and oxysterol‐binding protein to combat SARS‐CoV‐2 infection?
  著者:: Shahmohamadnejad, Shiva, 等
  出版事項: (2020)
• Rationale for Effective Prophylaxis Against COVID‐19 Through Simultaneous Blockade of Both Endosomal and Non‐Endosomal SARS‐CoV‐2 Entry into Host Cell
  著者:: Nabavi, Seyed Fazel, 等
  出版事項: (2021)
• Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
  著者:: Nabavi, Seyed Fazel, 等
  出版事項: (2020)